Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats

BJU International

Volumn 103, Issue 2, 2009, Pages 264-269

  Sakura, Mizuaki ^a   Masuda, Hitoshi ^a,b   Matsuoka, Yoh ^a   Yokoyama, Minato ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bladder; Cyclophosphamide; Rolipram; Type 4 phosphodiesterase

Indexed keywords

CYCLOPHOSPHAMIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NITRIC OXIDE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPHOSPHAMIDE; CYSTITIS; FEMALE; INTERLEUKIN-1BETA; NITRIC OXIDE; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149159857     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07948.x     Document Type: Article

References (30)

1. Gray KJ, Engelmann UH, Johnson EH et al. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol 1986 136 : 497 500
2. Etlik O, Tomur A, Deveci S et al. Comparison of the uroprotective efficacy of mesna and HBO treatments in cyclophosphamide-induced hemorrhagic cystitis. J Urol 1997 158 : 2296 9
3. Alfieri AB, Malave A, Cubeddu LX. Nitric oxide synthases and cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol 2001 363 : 353 7
4. Xu X, Cubeddu LX, Malave A. Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide treated rats. Eur J Pharmacol 2001 416 : 1 9
5. Ribeiro RA, Freitas HC, Campos MC et al. Tumor necrosis factor-α and interleukin-1β mediate the production of nitric oxide involved in the pathogenesis of ifosphamide induced hemorrhagic cystitis in mice. J Urol 2002 167 : 2229 34
6. Korkmaz A, Oter S, Deveci S et al. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol 2003 170 : 2498 502
7. Souza-Filho MV, Lima MV, Pompeu MM et al. Involvement of nitric oxide in the pathogenesis of cyclophosphamide induced hemorrhage cystitis. Am J Pathol 1997 150 : 247 56
8. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998 157 : 351 70
9. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000 12 : 174 9
10. Beavo J, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994 46 : 399 405
11. Peter K, Hayley JH, Mauro P. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur J Pharmacol 1995 281 : 69 74
12. Mary SB, Joan O'LB, Miriam B et al. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding. Biochem Pharmacol 1996 51 : 949 56
13. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995 101 : 387 9
14. Sekut L, Yarnall D, Stimpson SA et al. Anti-inflammatory activity of phosphodiesterase (PDE) -IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995 100 : 126 32
15. Mark DO, Joel L, Liping H, Diane LR, David FS, Gail S. Enhanced protection from renal ischemia. Reperfusion injury with A2A-adenosine receptor activation and PDE4 inhibition. Kidney Int 2001 59 : 2114 25
16. Odashima M, Otaka M, Jin M et al. Rolipram, a specific type 4 phosphodiesterase inhibitor, ameliorates aspirin-induced gastric mucosal injury in rats. Dig Dis Sci 2005 50 : 1097 102
17. Matsuhashi T, Otaka M, Odashima M et al. Specific type 4 phosphodiesterase inhibitor ameliorates thioacetamide-induced liver injury in rats. J Gastroenterol Hepatol 2005 20 : 135 40
18. Matsuoka Y, Masuda H, Yokoyama M, Kihara K. Protective effects of heme oxygenase-1 against cyclophosphamide-induced haemorrhagic cystitis in rats. BJU Int 2007 100 : 1402 8
19. Masuda H, Chancellor MB, Kihara K, Yoshimura N. 15-deoxy-Delta12,14- prostaglandin J2 attenuates development of cyclophosphamide-induced cystitis in rats. Urology 2006 67 : 435 9
20. Luo J, Zha S, Gage WR et al. α-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002 62 : 2220 6
21. Van Langendonckt A, Casanas-Roux F, Dolmans MM, Donnez J. Potential involvement of hemoglobin and heme in the pathogenesis of peritoneal endometriosis. Fertil Steril 2002 77 : 561 70
22. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004 25 : 430 6
23. Elena G, Douglas LF. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J 1999 13 : 2125 37
24. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol 2006 147 : S252 7
25. Robichaud A, Stamatiou PB, Jin SL et al. Deletion of phosphodiesterase 4D in mice shortens alpha (2) -adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002 110 : 1045 52
26. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFalpha responses. Proc Natl Acad Sci USA 2002 99 : 7628 33
27. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signalling. J Biol Chem 2003 278 : 5493 6
28. Oger S, Behr-Roussel D, Gorny D et al. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Eur Urol 2007 51 : 772 81
29. Kaiho Y, Nishiguchi J, Kwon DD et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic chorinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 2007 101 : 615 20
30. Barnes PJ, Pauwels RA. Theophylline in the management of asthma; time for reappraisal? Eur Respir J 1994 7 : 579 91